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In Gram-negative s ptic shock, human monocytes synthesize and express on their cytoplasmic membrane tissue factor (TF), a potent activator 
of the coagulation cascades. The role of TF in triggering disseminated intravascular coagulation (DIC) in these patients appears to be clear. We 
report he suppressive effect of interleukin-10 (IL-10) on endotoxin-induced TF activity and antigen levels, and on the expression of TF mRNA 
levels in human monocytes. These results emphasize the potential therapeutic value of this cytokine in septic shock, a condition still associated 
with a high mortality rate. 
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1. INTRODUCTION 
After incubation with Gram-negative endotoxin in 
vitro, blood monocytes ynthesize and express mem- 
brane tissue factor (TF), a potent initiator of the coagu- 
lation cascades [1]. Mononuclear cells from patients 
with meningococcemia also show TF activity, that cor- 
relates with the prognosis of the disease [2]. Since anti- 
TF antibodies prevent or attenuate endotoxin- and TF- 
induced disseminated intravascular coagulation (DIC) 
in animal experimental models [3,4], the role of TF in 
triggering DIC in Gram-negative s ptic shock appears 
clear. 
Interleukin-10 (IL-10) is a 3540 kDa protein pro- 
duced in various conditions of immune inactivation, by 
the TH0 and TH2 subsets of helper T cells, as well as by 
monocytes, macrophages and B cells [5]. It exerts a wide 
array of immunostimulatory effects on B cells [5] to- 
gether with a number of immunosuppressive effects on 
monocytes and macrophages. In vitro, IL-10 inhibits 
monocyte production of several inflammatory media- 
tors, including interleukin-1 (IL-1) a and fl, interleukin- 
6, interleukin-8, granulocyte colony-stimulating factor 
and tumor necrosis factor (TNF) a, while it upregulates 
the expression of the IL-1 receptor antagonist [5]. These 
properties uggest hat IL-10 might be a potent anti- 
inflammatory reagent in a variety of disease settings 
including septic shock. 
The aim of this study was to investigate the effect of 
IL-10 on TF activity, immunological expression and 
mRNA in LPS-activated monocytes. 
*Corresponding author. Fax: (33) (1) 4025-8853. 
2. MATERIALS AND METHODS 
Mononuclear cell suspensions containing 20-30% monocytes and 
7~80% lymphocytes were isolated by Ficoll-Hypaque gradient sedi- 
mentation as described in [6]. To obtain monocyte-enriched prepara- 
tions (75 95%), monocytes were further purified by adherence togel- 
atin/fibronectin-coated p tri dishes [7]. Cell suspension or adherent 
monocytes were incubated with or without IL-10 for 30 min at 37°C, 
under 5% CO 2, in RPMI medium supplemented as described in [6], 
before stimulation with 10 ng/ml LPS for 1 6 h. Purified human IL-10 
was generously provided by DNAX, Palo Alto, CA. After incubation, 
the supernatant was discarded and cells were washed and stored for 
less than one week at -80°C until TF measurement or RNA extrac- 
tion. Since monocytes are the only circulating cells to produce TF, 
mononuclear cell suspensions were used to measure TF activity and 
TF antigen levels, while adherent monocytes were used for RNA 
extraction; TF activity was also measured in the latter. 
After thawing, cells were lysed and TF activity was assayed as 
described in [6,7]. PCA was expressed asTF milliunits/106 monocytes. 
To determine what proportion of PCA was TF-initiated, residual PCA 
was measured, in some experiments, after incubating the cell lysate 
with a pool of neutralizing anti-TF monoclonal ntibodies (TF8-5G9, 
TF8-6B4, and TF9-9C3) at 10 ,ug/ml. The antibodies were generously 
given by T.S. Edgington [8]. 
Total RNA was extracted by the guanidinium-thiocyanate/cesium 
chloride method [7]. Filters were hybridized for 24 h at 42°C, simulta- 
neously to the TF and G3PDH cDNA probes. The autoradiograms 
were scanned by means of laser densitometry, using the Sebia Prefer- 
ence R apparatus, for the relative levels of mRNA in treated and 
untreated monocytes. 
cDNA probes were labeled with [~-32p]dCTP (3000 Ci/mmol) by 
random hexamer primer extension, using the Amersham Multiprime 
kit. The 641 bp TF cDNA probe kindly provided by T.S. Edgington 
[9] was excised from plasmid pUC8 with EcoRI. The G3PDH probe 
was purchased from Clontech (Palo Alto, CA). 
TF antigen was determined byan ELISA method using the Imubind 
TF kit (American Diagnostica Inc., Greenwich) according to the man- 
ufacturer's instructions, with slight modifications. Cells were solubil- 
ized in PBS containing 1% Triton X-100 and directly transferred to
the EL1SA plate. 
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Fig. 1. IL-10 concentration-dependent inhibition of LPS-induced TF 
activity. Mononuclear cell suspensions were pretreated with increasing 
concentrations of IL-10 for 30 min and subsequently stimulated with 
LPS (10 ng/ml) for 4 h. Data are the percentage of the maximal 
response obtained in the absence of IL-10. Results are given as the 
mean + S.E.M. of four experiments. 
3. RESULTS AND DISCUSSION 
We first investigated the effect of  graded concentra- 
tions of  IL-10 on LPS- induced functional TF  activity in 
human monocytes.  Freshly collected mononuc lear  cells 
had no detectable procoagulant  activity (PCA) (clotting 
times >160 s). After  incubation,  the PCA of  LPS- 
treated cells was 2732 +_ 230.7 milliunits/106 monocytes 
(mean + S.E.M. of  4 separate xperiments). PCA was 
identified as TF, since more than 99% was inhibited by 
a mixture of  neutral iz ing monoclonal  ant ibodies to 
human TF. Increasing IL-10 concentrat ions (0.1-50 U/ 
ml) inhibited LPS- induced TF  activity of  mononuc lear  
cells in a concentrat ion-dependent  manner.  IL-10 at 25 
U/ml inhibited 70% of total TF  activity (Fig. 1); no 
further inhibit ion was obtained at higher concentrat ions 
of  IL-10. 
In paral lel  to the effect on TF  activity, IL-10 had a 
concentrat ion-dependent  inhibitory effect on TF  anti- 
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Fig. 2. Correlation between TF antigen expression (ELISA) and TF 
activity of LPS-exposed monocytes, in the presence of increasing con- 
centrations of IL-10 (0, 0.1, 1, 10 and 25 U/ml). The results are given 
as the percentage of maximal TF expression induced by LPS (10 
ng/ml) in the absence of IL-10. 
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Fig. 3. Kinetics of IL-10 inhibition of LPS-induced TF activity from 
0 to 6 hours (mean + S.E.M., n = 3). Mononuclear cells were incu- 
bated for 30 min, 1, 2, 3, 4 and 6 h with RPMI medium alone, LPS, 
IL-10 or LPS + IL-10. 
gen levels measured by means of  an EL ISA.  As shown 
in Fig. 2, TF  activity and antigen levels measured in 
paired experiments correlated strongly ( r=0.927,  
P < 0.001), ruling out the involvement of  the TF  path- 
way inhibitor (TFPI )  in the observed effect [10]. 
We then compared TF  activity of  monocytes exposed 
to LPS for various times (04  h), with or without IL-10 
pretreatment (Fig. 3). After  the addit ion of  LPS, TF  
activity increased gradual ly  from 0 to 6 h. When IL-10 
was added, TF  activity decreased as early as the second 
hour after the addit ion of  LPS, the effect was max imum 
at 3 h and cont inued at 4 and 6 h. Thus IL-10 acted on 
an early step of  TF  product ion,  as it does on IL-1 and 
TNF  alpha product ion [11]. 
We then evaluated the effect of  IL-10 on TF  mRNA 
levels in LPS-st imulated adherent monocytes.  TF  
mRNA was not detectable in unst imulated monocytes 
(Fig. 4). Exposure to 10 ng/ml of  LPS for 4 h was 
associated with high TF  mRNA levels. The addit ion of  
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Fig. 4. IL-10 induced a concentration-dependent inhibition of LPS- 
induced TF mRNA. Five fig of total RNA was analysed by Northern 
blotting. RNA was extracted from untreated monocytes (1) and from 
cells exposed for 4 h to 10 ng/ml LPS (2) or to LPS + IL-10 at 0.1 (3) 
and 10 (4) U/ml. The membranes were hybridized to TF and G3PDH 
probes. 
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Fig. 5. Effect of IL-10 on the stability of LPS-induced TF mRNA. 
Monocytes were xposed to LPS for 2 h to induce TF mRNA. Actino- 
mycin D (10/~g/ml) was added, followed by IL-10 (10 U/m1). Total 
RNA was harvested atthe indicated times after the addition of actino- 
mycin D, and analyzed by Northern blotting (A). Autoradiograms 
were scanned by means of laser densitometry. The stability of the 2.3 
kb TF mRNA species i shown (B). 
0.1 and l0 U/ml IL-10 was associated with a concentra- 
tion-dependent decrease in TF mRNA (Fig. 4). We 
checked that IL-10 had the same inhibitory effect on TF 
activity generated by adherent monocytes and cells in 
suspension (data not shown). 
Activation of monocytes and macrophages plays an 
important role in immune responses against microor- 
ganisms and tumors. IL-10 has already been shown to 
inhibit the secretion of a number of cytokines by inhib- 
iting cytokine-specific mRNA synthesis induced by LPS 
[11]. In this study, we show that IL-10 also inhibits TF 
production at the mRNA level. 
The rate of mRNA degradation is an important regu- 
latory mechanism that may control the level of gene 
expression. The half-life of the TF mRNA was exam- 
ined, with and without IL-10 pretreatment. As shown 
in Fig. 5, the yield of total RNA decreased similarly in 
the presence and absence of IL-10. The half-life of TF 
mRNA was approximately 2 h in both conditions. This 
indicates that IL-10 does not alter the half-life of TF 
mRNA and suggests an effect of IL-10 at the transcrip- 
tional level. Conflicting results have been reported as 
concerns the mechanism of the inhibitory effect of IL-10 
on TNF-~ mRNA expression. According to de Waal 
Malefyt et al. [12], the inhibition of TNF-~ secretion, 
like that of other cytokines, occurs at the transcriptional 
level, whereas Bogdan et al. [11] found no suppressive 
effect on the transcription of the corresponding enes 
and concluded that IL-10 promotes the degradation of 
cytokine mRNAs. 
Two studies from independent laboratories recently 
showed that IL-10 was highly effective at protecting 
mice from lethal endotoxin shock, an undesirable 
monokine-mediated inflammatory reaction [13,14]. In- 
terestingly, this was the case whether IL-10 was admin- 
istered concurrently with or 30 min after the injection 
of endotoxin [14]. The protective ffect was associated 
with a substantial decrease in endotoxin-induced TNF-  
release. 
The intravascular expression of TF, and the increase 
in plasma levels of TNF alpha and IL-1, have been 
implicated in the onset of the multiple organ failure 
syndrome observed in Gram-negative s ptic shock [15]. 
The demonstration that IL-10 is capable of inhibiting 
the production of both molecules imultaneously is thus 
of considerable interest for the treatment of this often 
fatal condition [16]. 
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